Hiraishi, Itaru
Ueno, Rie
Watanabe, Asuka
Maekawa, Shinichiroh
Funding for this research was provided by:
MSD K.K.
Article History
Accepted: 17 October 2021
First Online: 16 November 2021
Declarations
:
: This article was funded by MSD K.K., Tokyo, Japan. The authors had full control of the content, and approved the final version
: Itaru Hiraishi, Rie Ueno, Asuka Watanabe, and Shinichiroh Maekawa are employees of MSD K.K., Tokyo, Japan which sponsored the research and manuscript development. The authors have no other conflicts of interest to declare.
: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA’s data sharing policy, including restrictions, is available at http://engagezone.msd.com/ds_documentation.php. Requests for access to the study data can be submitted through the Engage Zone site or via email to dataaccess@merck.com.
: Not applicable.
: All authors participated in the writing, editing, and critical revision for intellectual content, and approval of the final version of this manuscript. All authors met ICMJE authorship criteria and agree to be accountable for all aspects of the work.
: This survey was carried out in accordance with Good Post-Marketing Study Practice for Drugs as specified by the Ministry of Health, Labor and Welfare in Japan. A research protocol was created for the survey and was approved by an external Institution Review Board.
: According to Good Post-Marketing Study Practice in Japan, informed consent was not required for this post-marketing survey. As such, informed consents were voluntarily obtained from the individual participants in some facilities and all facilities agreed to use the survey data by a contract or an agreement form with MSD K.K., Tokyo, Japan.
: Not applicable.